TPP Bill's Biologics Language Could Limit Future Changes, Spur Arbitration

Codifying 12 years of market exclusivity for biologics in the Trans-Pacific Partnership implementing bill, as pushed by Senate Finance Committee Chairman Orrin Hatch (R-UT) in talks with the White House, could make it more difficult to cut exclusivity periods in the future, sources tell Inside Health Policy . Should Hatch's requests be honored, any future U.S. move to cut exclusivity could also prompt legal action under TPP's controversial arbitration system, according to one government expert. Hatch told Inside U.S. Trade...